In the EU<unk>  is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Dolutegravir/lamivudine
Abacavir/lamivudine
Lamivudine/tenofovir
Lamivudine/raltegravir
Lamivudine/zidovudine
Atazanavir/ritonavir
Dolutegravir/rilpivirine
Doravirine/lamivudine/tenofovir